ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2498

The Methylome Profile of B-cells as a Biomarker of Nephritis in IgA Vasculitis

Veronica Pulito-Cueto1, Joao Carlos Batista-Liz1, Laura Carmen Terron2, Iván Fernández Rengel3, María Sebastián Mora-Gil4, María Teresa Leonardo5, Ana Peñalba5, Luis Martín-Penagos6, Lara Belmar-Vega7, Cristina Gomez-Fernandez8, Ligia Gabrie-Rodriguez9, Rafael Gálvez Sánchez9, Luis Caminal-Montero10, Ana Turrion Nieves11, Patricia Quiroga Colina12, Esther Vicente-rabaneda13, Belén Sevilla-Pérez14, José Luis Callejas15, Eduardo Andrés-León2, Javier Martin16, Ana María Marquez17, Santos Castañeda13, Ricardo Blanco-Alonso18 and Raquel Lopez-mejias1, 1IDIVAL, Santander, Spain, 2Unidad de Bioinformática, Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, Granada, Spain, 3Bioinformatics Unit, Institute of Parasitology and Biomedicine López-Neyra (IPBLN), CSIC, GENYO, Cen, Granada, Spain, 4Immunopathology Group, IDIVAL, Santander, Spain, 5Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 6Immunopathology Group, IDIVAL. Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 7Immunopathology Group, IDIVAL. Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, 8Division of Dermatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 9Immunopathology Group, IDIVAL. Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 10Internal Medicine Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain, 11Rheumatology Department, Hospital Universitario Virgen de la Vega, Salamanca, Spain, 12Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, 13Hospital Universitario de La Princesa, Madrid, Spain, 14Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, 15Systemic Autoimmune Diseases Unit, Hospital Clinico San Cecilio, Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Granada, Spain, 16Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Spain, Granada, Spain, 17Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Granada, Spain, 18Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

Meeting: ACR Convergence 2024

Keywords: B-Lymphocyte, Biomarkers, Epigenetics, Nephritis, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Nephritis is the main cause of long-term morbidity and mortality in patients with Immunoglobulin-A vasculitis (IgAV) [1, 2]. Unfortunately, sensitive, specific, and non-invasive biomarkers are no available for the diagnosis of nephritis and the identification of IgAV patients with a high risk of developing severe renal complications [3]. In this regard, B-cells have been proposed as the main cell type involved in the pathogenesis of IgAV, and preliminary results of our group have pointed to methylation profiles of B-cells as biomarkers of the susceptibility of IgAV. Nevertheless, whether B-cells are also key players in the development of nephritis and could be used as biomarkers of this complication in IgAV is still unknown. Accordingly, the main aim of our study was to determine the role of peripheral B-cells in the renal damage characteristic of IgAV, by performing the first exhaustive analysis of the methylome of peripheral B-cells.

Methods: 29 Caucasian patients with IgAV, who were in the acute phase of the disease, were recruited. Among these patients, 16 (55.2%) developed nephritis. Peripheral blood mononuclear cells were isolated from all the patients by density gradient using Ficol. B-cells were purified using magnetic cell separation by MACS® Technology. Finally, genomic DNA was extracted from each B-cell and bisulfite-converted with the EZ DNA MethylationTM kit and hybridized onto an Infinium MethylationEPIC Bead Chip array.

Results: Our results unveiled profound alterations in the DNA methylation profiles of B-cells between patients with IgAV who developed nephritis and those without this complication. 7656 differentially methylated positions (DMPs) across the whole genome were identified between these groups of individuals. Among them, 7581 were located in one or more genes, whereas the remaining 75 were not associated with any gene (Figure 1). Interestingly, through gene ontology (GO) analysis of these data, we observed an enrichment in several biological processes of the immune response (Figure 2). Moreover, an enrichment in other biological processes, including ganglioside metabolic process, atrial septum primum morphogenesis, and regulation of inositol, among others, was disclosed (Figure 2).

Conclusion: Our results point to the methylation profile of B-cells as a non-invasive biomarker for the diagnosis of renal damage in IgAV.

[1] Autoimmun Rev 2018;17:301-15.; [2] J Am Soc Nephrol 2002;13:1271-8; [3] J Clin Med 2021;10:2310.

Fundings: European Union FEDER funds and “Fondo de Investigaciones Sanitarias” from “Instituto de Salud Carlos III” (ISCIII, Health Ministry, Spain), (PI18/00042 and PI21/00042). JCBL: PFIS program fellowship from the ISCIII, co-funded by the European Social Fund (`Investing in your future´), (FI22/00020). RL-M: Miguel Servet type II program fellowship from the ISCIII, co-funded by ESF (“Investing in your future” (CPII21/00004).

Supporting image 1

Figure 1. Count histogram of differentially methylated positions (DMPs) between patients with IgA vasculitis with and without nephritis.

Supporting image 2

Figure 2. Gene Ontology (GO) enrichment analysis of biological processes of differentially methylated positions (DMPs) between patients with IgA vasculitis with and without nephritis.


Disclosures: V. Pulito-Cueto: None; J. Batista-Liz: None; L. Terron: None; I. Fernández Rengel: None; M. Sebastián Mora-Gil: None; M. Leonardo: None; A. Peñalba: None; L. Martín-Penagos: None; L. Belmar-Vega: None; C. Gomez-Fernandez: None; L. Gabrie-Rodriguez: None; R. Gálvez Sánchez: None; L. Caminal-Montero: None; A. Turrion Nieves: None; P. Quiroga Colina: None; E. Vicente-rabaneda: None; B. Sevilla-Pérez: None; J. Callejas: None; E. Andrés-León: None; J. Martin: None; A. Marquez: None; S. Castañeda: Bristol-Myers Squibb(BMS), 2, 6, Eli Lilly, 2, 6, Merck/MSD, 2, 5, 6, Pfizer, 5, Roche, 2, 6, UCB, 2, 5; R. Blanco-Alonso: AbbVie, 2, 5, 6, Bristol-Myers Squibb, 2, 6, Galapagos, 6, Janssen, 2, 6, Lilly, 2, 6, MSD, 2, 5, 6, Pfizer, 2, 6, Roche, 2, 5, 6; R. Lopez-mejias: None.

To cite this abstract in AMA style:

Pulito-Cueto V, Batista-Liz J, Terron L, Fernández Rengel I, Sebastián Mora-Gil M, Leonardo M, Peñalba A, Martín-Penagos L, Belmar-Vega L, Gomez-Fernandez C, Gabrie-Rodriguez L, Gálvez Sánchez R, Caminal-Montero L, Turrion Nieves A, Quiroga Colina P, Vicente-rabaneda E, Sevilla-Pérez B, Callejas J, Andrés-León E, Martin J, Marquez A, Castañeda S, Blanco-Alonso R, Lopez-mejias R. The Methylome Profile of B-cells as a Biomarker of Nephritis in IgA Vasculitis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/the-methylome-profile-of-b-cells-as-a-biomarker-of-nephritis-in-iga-vasculitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-methylome-profile-of-b-cells-as-a-biomarker-of-nephritis-in-iga-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology